Jensen BV, Schou JV, Yilmaz M, Johannesen HH, et al. Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status. Int J Cancer 2020 Dec 17. doi: 10.1002/ijc.33448.
PMID: 33336394